| Overview |
| bs-11601r-bf350-100ul |
| SRGAP1 Polyclonal Antibody, AbBy Fluor-350 Conjugated |
| WB, IF(IHC-P) |
| Human, Mouse, Rat |
| Specifications |
| AbBy Fluor-350 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human SRGAP1 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| ARHGAP13; FLJ22166; KIAA1304; RGD1566260; Rho GTPase activating protein 13; SLIT ROBO Rho GTPase activating protein 1; SRGAP 1; SRGP1_HUMAN. |
| SRGAPs contain a highly conserved overall primary structure and play an important role in the cell facilitating Slit-robo signaling in cell migration and axon guidance. SRGAP1 (Slit-robo Rho GTPase activating protein 1), also known as ARHGAP13 (Rho GTPase activating protein 13), functions as a GTPase-activating protein for Cdc42 and Rho A. Expressed in kidney, testis, lung and brain, SRGAP1 contains an FCH (Fes/CIP4 homology) domain, a Rho-GAP domain and an SH3 domain. In the presence of Slit, SRGAP1 (via its SH3 domain) binds to the CC3 motif in robo (a protein responsible for mediating the repulsive effect of Slit) with higher affinity and inhibits Cdc42 activity in a robo/SRGAP-dependent manner. More specifically, SRGAP1 increases the intrinsic GTPase activity of Cdc42, thereby converting it to its inactive, GDP-bound form. Inactivation of Cdc42 ultimately leads to a decrease in actin polymerization. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
Powered by Bioz